Follow The Filings

FBLG FibroBiologics

FibroBiologics earnings company data as of 8:00 PM ET 10/28

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 30 Oct EPS -0.63 — —
Rev — — —

Insider trades

Open-market buys and sales by FBLG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FBLG insider trades
  • $121K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Hamid Khoja Chief Scientific Officer
    Buy
    $11K 30,000 shares at $0.3800 +96% to stake
    Traded Mar 4 Filed Mar 5
    ↗
  2. Pete O'Heeron CEO
    Buy
    $20K 51,500 shares at $0.3800 +0.9% to stake
    Traded Mar 2–4 Filed Mar 4
    ↗
  3. Jason Davis CFO
    Buy
    $29K 70,000 shares at $0.4100 New stake
    Traded Mar 2 Filed Mar 3
    ↗
  4. Ruben A Garcia General Counsel
    Buy
    $13K 40,000 shares at $0.3300 +29% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  5. Ruben A Garcia General Counsel
    Buy
    $48K 140,000 shares at $0.3400 New stake
    Traded Dec 11, 2025 Filed Dec 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 5.07,7.01,9.01 Filing Doc
SCHEDULE 13D — Filing Doc
8-K 1.01,3.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
10-Q Filing Doc
8-K 3.01 Filing Doc
424B3 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,9.01 Filing Doc
424B5 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.03,9.01 Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 11 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.